“
TL;DR
The central result was a significant increase in corneal nerve fiber density (CNFD) and a reduction in corneal nerve fiber width (CNFW) after treatment.
Diabetes · 15 authors, 12 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
The central result was a significant increase in corneal nerve fiber density (CNFD) and a reduction in corneal nerve fiber width (CNFW) after treatment.
The central result was a significant increase in corneal nerve fiber density (CNFD) and a reduction in corneal nerve fiber width (CNFW) after treatment. Clinically, tear breakup time improved and corneal/conjunctival punctate keratopathy scores decreased. Tear substance P concentrations increased significantly and were associated with the improvement in CNFD. Proteomic analysis suggested fenofibrate upregulated neurotrophin signaling and modulated lipid metabolism while suppressing complement and inflammatory pathways. Limitations include the lack of a randomized control group, a short follow-up, and the inability of corneal esthesiometry to detect subtle nerve changes.